期刊文献+

处方事件监测 被引量:8

Prescription Event Monitoring
下载PDF
导出
摘要 处方事件监测用非干预性、观察性药品不良反应监测方法, 1981年在英国最早开展。本文简要回顾其发展历史背景,详细描述其操作过程,介绍其开展现状。尽管处方事件监测的开展有相当的难度,但是作为监测药品不良反应的一种方法,它已成为药品上市后安全警戒体系中一种重要的研究方法,可以作为药品不良反应监测自愿报告系统的有益补充。 Prescription Event Monitoring (PEM) is a non-interventional observational method of adverse drug reaction monitoring, which was established first in England in 1981. This review introduces the background of development, the details of procedure and the current situation. It is quite difficult to make PEM studies, but as a method of adverse drug reaction monitoring, it has become an important method of post-marketing surveillance system and can complement spontaneous reporting system of adverse drug reaction.
作者 张亮 王大猷
出处 《中国药物警戒》 2005年第1期4-6,共3页 Chinese Journal of Pharmacovigilance
关键词 处方事件监测 药物警戒 药品不良反应 流行病学方法 Prescription Event Monitoring Pharmacovigilance Adverse drug reaction
  • 引文网络
  • 相关文献

参考文献8

  • 1[1]Inman WH.Postmarketing surveillance of adverse drug reactions in general practice.II:Prescription-event monitoring at the University of Southampton[J].Br Med J (Clin Res Ed),1981,282(6271):1216-1217.
  • 2[2]Inman WH.Prescription-event monitoring and yellow cards[J].Lancet,1984,1(8389):1301.
  • 3[3]Mann RD.Prescription-event Monitoring.In:Strom BL,ed[M].Pharmacoepidemiology.3rd.Chichester:John Wiley & Sons Ltd,2000,231-246.
  • 4[4]Shakir SW.PEM in the UK.In:Mann RD,ed[M].Pharmacovigilance.Chichester:John Wiley & Sons Ltd,2002,333-344.
  • 5[5]Emerson A,Martin RM,Tomlin M,et al.Prospective cohort study of adverse events monitored by hospital pharmacists.Hospital Adverse Event Monitoring Study (HAEMS) Group[J].Pharmaeoepidemiol Drug Saf,2001,10(2):95-103.
  • 6[6]Coulter DM.PEM in New Zealand.In:Mann RD,ed[M].Pharmacovigilance.Chichester:John Wiley & Sons Ltd,2002,345-362.
  • 7[7]Kubota K.Prescription-event monitoring in Japan (J-PEM)[J].Drug Saf,2002,25(6):441-444.
  • 8[8]Kubota K,Kawabe E,Hinotsu S,et al.Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics[J].Eur J Clin Pharmacol,2001,56(11):831-838.

同被引文献78

  • 1张晓红,lin bing-liang,杨绍基,gao zhi-liang.拉米夫定停药后出现肝衰竭患者hbv基因型及基因变异[J].中华临床感染病杂志,2008,1(2). 被引量:4
  • 2刘智勇,张志泽.论政府公共危机治理能力的缺失和再造[J].电子科技大学学报(社科版),2004,6(3):96-99. 被引量:13
  • 3阿金.伯恩,李瑞昌,许雷雷.危机研究的经验[J].经济社会体制比较,2006(5):20-27. 被引量:9
  • 4顾牛范 吴文源.精神药物不良反应监测[J].新药与临床,1985,4(4):228-228.
  • 5龚时薇,张亮,黄杰敏,詹学锋,姜卫,王成江.药品安全与风险管理[J].中国药房,2007,18(22):1687-1690. 被引量:45
  • 6李福胜.国家风险[M].北京:社会科学文献出版社,2006:11.
  • 7人民网.1992-10-23法国输血丑闻案审判结束[EB/OL].[ 2008-01-23 ] . http: //www. gzdaj. gov. cn/dnjr/sjdnjr/ 200710/t20071023 _ 8462. htm.
  • 8路透社电讯.日本通过法律补偿血液污染丑闻中的受害人[EB/OL].[2008-01-11].http://cn.reuters.com/article/asiaNews/idCNChina-4719200801117sp-true.
  • 9伊恩I米特罗夫.危机防范与对策[M].北京:电子工业出版社,2004:2-5.
  • 10郭晓亭 蒲勇健 林略.风险概念综述及其数量刻画.统计与精算,2004,(2):24-27.

引证文献8

二级引证文献63

相关主题

;
使用帮助 返回顶部